Media
Follow our progress and stay up to date with our press releases and media coverage.
Press Releases
GeneVentiv Therapeutics Receives Funding from the North Carolina Biotechnology Center
June 7, 2022 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced the award of a $250,000 Strategic Research Loan (SRL) from the North Carolina...
GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the treatment of Hemophilia A or B with or without inhibitors
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
GeneVentiv Therapeutics Expands Scientific Advisory Board
March 3, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective, and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the expansion of...
GeneVentiv Announces Appointment to Scientific Advisory Board
January 12, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the...
Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia
GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene...
In the News
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.